MDElliottMD: Create Vardenafil scaffold

2026-05-15T15:30:25Z

Create Vardenafil scaffold

New page

{{MedTemplate
| generic = Vardenafil
| brand = Levitra, Staxyn
| classes = PDE5 Inhibitor
| uses = <vote slug="erectile-dysfunction-use">Erectile dysfunction</vote>
| starting_dose = 10 mg ~1 h before sexual activity
| preparations = 2.5, 5, 10, 20 mg tabs (Levitra); 10 mg ODT (Staxyn)
| fda_max = 20 mg/d
| routes = Oral
| onset = ~30 min
| duration = 4–5 h
| halflife = 4–5 h
| bioavailability = ~15% (extensive hepatic first-pass)
| pregnancy = Category B
| legal = Rx-only in US
| mechanism = Selective inhibitor of PDE5. Slightly higher PDE5/PDE6 selectivity vs sildenafil (less visual side effect) but more PDE1 cross-activity (occasional QT effects at high doses).
| intro = Vardenafil is a PDE5 inhibitor very similar to [[Sildenafil]] in onset and duration, marketed mainly for erectile dysfunction. Same nitrate contraindication and alpha-blocker caution. Slightly different selectivity profile but in practice the three short-acting PDE5 inhibitors are nearly interchangeable; choice is often driven by patient preference and insurance.
| indications =
| dosing =
| effects =
| pk_absorption = ~15%; reduced by high-fat meals.
| pk_distribution = Plasma protein binding ~95%.
| pk_metabolism = Hepatic via CYP3A4 (primary).
| pk_elimination = Fecal as metabolites.
| pharmacodynamics =
| interactions = <pharmaInteractions/>
| pregnancy_details =
| monitoring = Blood pressure; ECG (QT) in congenital long-QT.
| counseling = Contraindicated with any nitrate. Avoid in congenital long-QT syndrome or with type-1A/type-3 antiarrhythmics.
| anecdotes =
| seealso = [[Avanafil]], [[Sildenafil]], [[Tadalafil]]
| references = <references/>
}}

[[Category:PDE5 Inhibitors]]
[[Category:Medicines]]

Vardenafil - Revision history

MDElliottMD: Create Vardenafil scaffold